Universal reference book for medicines
Product name: ULKAWIS (ULCAVIS)

Active substance: bismuthate, tripotassium dicitrato

Type: The drug has a protective effect on the mucous membrane of the stomach and duodenum.
Antiulcer drug
Manufacturer: KRKA dd, Novo mesto (Slovenia)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

Antiulcer agent with bactericidal activity against Helicobacter pylori.
It also has an anti-inflammatory and astringent effect. In the acidic environment of the stomach forms insoluble bismuth oxychloride and citrate, and also chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. Increasing the synthesis of prostaglandin E, the formation of mucus and the secretion of bicarbonate, stimulates the activity of cytoprotective mechanisms, increases the stability of the mucous membrane of the gastrointestinal tract to the effects of pepsin, hydrochloric acid (hydrochloric acid), enzymes and bile salts. It leads to the accumulation of the epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.
Bismuth tricalcium dicitrate is practically not absorbed from the digestive tract.
However, a small amount of bismuth can enter the systemic circulation. It is excreted mainly with feces. An insignificant amount of bismuth, which enters the plasma, is excreted by the kidneys.
Peptic ulcer of the stomach and duodenum in the phase of exacerbation (including associated with Helicobacter pylori);
chronic gastritis and gastroduodenitis in the phase of exacerbation (including associated with Helicobacter pylori); irritable bowel syndrome, mainly with symptoms of diarrhea; functional dyspepsia, not associated with organic gastrointestinal diseases.
Adults and children older than 4 years - inside 2-4 times / day for 30 minutes before meals.
The dose depends on the age of the patient.
The course of treatment is 4-8 weeks.
For the next 8 weeks, do not take drugs containing bismuth.
For the eradication of Helicobacter pylori, it is advisable to use bismuth tricalium dicitrate in combination with antibacterial drugs possessing anti-Helicobacter pylori activity.

From the digestive system: transient effects are possible - nausea, vomiting, frequent stools, constipation.

Dermatological reactions: skin rash, itching.

From the side of the central nervous system: with prolonged use in high doses - encephalopathy associated with the accumulation of bismuth in the central nervous system.

Severe renal dysfunction, pregnancy, lactation, hypersensitivity to bismuth tricalium dicitrate.

Contraindicated in pregnancy and lactation (breastfeeding).

Contraindicated in marked violation of kidney function.

It is used in children older than 4 years according to the dosing regimen.

Do not use for more than 8 weeks.

During treatment it is not recommended to exceed the established daily doses for adults and children.

At the end of the course treatment at recommended doses, the concentration of active substance in the blood plasma does not exceed 3-58 Ојg / l, and intoxication is observed only at a concentration of more than 100 Ојg / l.

Against the background of application, it is possible to stain the feces black due to the formation of bismuth sulphide.
Sometimes there is a slight darkening of the tongue.
With the simultaneous administration of other medicines, as well as food and liquids, in particular antacids, milk, fruits and fruit juices, a change in the efficiency of bismuth in tricalium dicitrate is possible.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!